East Hill Management NewsDomantis LimitedDecember 2006Glaxosmithkline to Acquire Domantis ₤230 Million GSK Will Further Expand Its Biopharmaceuticals Portfolio With Acquisition of Pioneering Antibody Technology London - Friday 8 December 2006 - GlaxoSmithKline plc (GSK) today announces that it has entered into an agreement to acquire Domantis Ltd, a leader in developing the next generation of antibody therapies, for ₤230 million (US$454 million) in cash. Domantis, a privately owned company, will become part of GSK’s Biopharmaceuticals Centre of Excellence for Drug Discovery (CEDD) while continuing to operate from laboratories in Cambridge, UK. [More] October 2006Domantis Launches Major Recruitment Initiative. Domantis is launching a major recruitment drive as we seek to expand our therapeutic pipeline. With this in mind we are looking to recruit bench scientists from a wide-range of disciplines related to dAb product generation. Applications from specialists in biological assay development, protein expression, molecular biology and antibody engineering are encouraged. Domantis offer a creative, dynamic and fast-paced working environment, competitive salaries, private medical cover, a contributory pension scheme and a generous share option package. [More] July 2006Domantis first to win UK innovation in drug discovery & development award. Domantis, the human Domain Antibody (dAb) therapeutics company, is the first winner of the UK Innovation in Drug Discovery & Development Award, one of three new BioEntrepreneur Awards sponsored by London First and UK Trade & Investment. [More] June 2006Gregory Perry joins Domantis as CFO. Domantis, the human Domain Antibody (dAb) therapeutics company, today announced that Gregory Perry has joined the Company as its first Chief Financial Officer. Perry comes to Domantis with over 20 years of experience in senior financial management for major American companies including PerkinElmer, Honeywell and General Electric (GE) and was most recently SVP and CFO at Transkaryotic Therapies (TKT). [More] June 2006Domantis granted broad European patent rights to pioneering half-life extension technology. Domantis, the human Domain Antibody (dAb) therapeutics company, today announced the grant of EP1517921B with broad composition of matter claims protecting its “AlbudAb” technology. AlbudAbs are dAbs that specifically bind to serum albumin and can dramatically enhance the half-life and efficacy of any molecule attached to them. The granted patent covers two or more dAbs linked to one another, where at least one dAb binds to serum albumin. The patent is the first to grant of a series of filings based on Domantis’ pioneering AlbudAb approach. Domantis’ lead AlbudAb program will enter late stage pre-clinical testing this year. [More] December 2005Domantis Raises $29 Million in Series B Financing. Novo Nordisk Makes $8 Million Strategic Investment. Domantis, the human Domain Antibody (dAb) therapeutics company, today announced that it has raised US$29 million (£17 million) from new investors Novo Nordisk and MC Life Science Ventures, Inc. ( a subsidiary of Mitsubishi Corporation), together with its existing investors. Domantis has raised a total of $83 million since its inception in 2000. [More] December 2005Revolutionary Approach to Cancer Therapy Should Increase Efficacy, Reduce Toxicity for Many Oncology Indications. Domantis, the human Domain Antibody (dAb) therapeutics company, today presented data showing how dual targeting dAbs (a pair of linked dAbs in a single product, each of which binds to a different target) have been used to specifically target multiple myeloma cells, while sparing healthy cells. [More] December 2005Domantis Limited, the human Domain Antibody (dAb) therapeutics company, today announced a multi-target discovery collaboration with Bristol-Myers Squibb Company (NYSE: BMY) to develop dAb therapeutics for uses in the fields of immunology and oncology. Glycoform LimitedJanuary 2007GlycoForm announces first in vivo data from a Novel Synthetic Glycoprotein and additional $1.1 million in funding July 2006Research Collaboration between Cambridge Antibody Technology and Glycoform Ltd
Glycoform today announces that it has entered into a research collaboration with NanotectureOctober 2006Nanotecture wins IChemE s Shell Energy Award Nanotecture Ltd, the fast growing nanotechnology materials company, has won the Shell Energy Award from the Institution of Chemical Engineers ( IChemE ) for its innovative supercapacitor technology that could significantly reduce CO2 and other diesel engine emissions by eliminating the need to idle truck engines to provide power for electrical loads. This change is being driven by recent legislation, now enacted in most states of the USA, that prevents drivers from idling their engines for more than few minutes (except in the case of emergency). Instead, electrical loads are sustained by the engine starting batteries; which are recharged once the supercapacitor has started the engine. [More] May 2006Nanotecture awarded DTI grant for Nanoporous Active Cathodes for Primary Lithium Batteries. Nanotecture Ltd, the fast growing nanotechnology materials company, announces that it has been awarded a £131,000 grant by the UK’s Department of Trade & Industry (DTI) through the Technology Programme, to support a two year research and development project entitled “Nanoporous Active Cathodes for Primary Lithium Batteries”. The project involves a collaboration between Nanotecture Ltd and Ultralife Batteries (UK) Ltd. It will combine Nanotecture’s novel materials technology with Ultralife’s lithium battery engineering and manufacturing skills. [More] February 2006Nanotecture awarded DTI grant for Next Generation Super-Capacitors for Hybrid Electric Vehicles. Nanotecture Ltd, the fast growing nanotechnology materials company, announces that it has been awarded a £374.6K grant by the UK’s DTI, to support a two year research and development project entitled “Next Generation Super-capacitors for Hybrid Vehicle Applications”. The project involves a collaboration between Nanotecture Ltd, Johnson Matthey Plc and HILTech Developments Ltd. It will combine Nanotecture’s novel materials technology with Johnson Matthey’s manufacturing skills and HILTech’s system engineering design capability. [More] Offshore Hydrocarbon MappingMarch 2007OHM and emgs resolve patent proceedings initiated by emgs over IP rights to SBL. London, 9 March 2007 – OHM and emgs have settled the patent infringement proceedings which emgs issued in October 2006 in the High Court of London relating to patent number GB2382875. Both companies have welcomed this early resolution of the dispute. [More] March 2007Offshore Hydrocarbon Mapping plc (OHM) (AIM:OHM) Electromagnetic Geoservices AS (emgs) agrees to discontinue patent proceedings against OHM emgs is discontinuing its proceedings in the High Court of London against OHM which alleged infringement of emgs' patents relating to Seabed Logging. OHM filed evidence with the Court seeking to demonstrate that emgs was mistaken in its belief that OHM's activities were infringing.[More] March 2007Trading update for six months to 28 February 2007 Further Positive Momentum Offshore Hydrocarbon Mapping (AIM:OHM) (“OHM” or “the Company”) is pleased to announce further positive momentum during the six months to 28th February 2007: New client enquiries remain at high levels, surveys have been completed successfully in Norway, UK, West Africa, and the South Atlantic and the Company has made further enhancements to its survey equipment, vessel chartering capacity and data processing offering.[More] February 2007Offshore Hydrocarbon Mapping continues to grow international operations Offshore Hydrocarbon Mapping plc (OHM) announced today that it is expanding its operations by moving to larger offices in both Houston, Texas and Singapore. The announcement follows the company’s recent commitment to a five-year charter of a dedicated Atlantic survey vessel to launch in May of 2007. [More] January 2007OHM Meets Growing CSEM Demand With Dedicated Survey Vessel: ‘OHM Express’ chartered for five years Offshore Hydrocarbon Mapping plc (“OHM or “the Company”) announced today that it has secured a dedicated CSEM vessel for a five-year charter with Norway-based Seatrans. The 110 metres long ‘OHM Express’ is due to launch in May 2007, and follows the Company’s November 2006 announcement of five-month charter survey of the CS Teneo.
Dave Pratt, Chief Executive Officer of OHM said: November 2006Placing of 1.5 million new ordinary shares raises approximately £1.9 million (the “Placing”) Offshore Hydrocarbon Mapping plc (AIM:OHM), a provider of remote electromagnetic sensing services, is pleased to announce that KBC Peel Hunt Ltd (“KBC Peel Hunt”) has conditionally placed 1.5 million new ordinary shares of 1p each (“Placing Shares”) (representing approximately 5% of the Company’s issued share capital) at 125p per Ordinary Share (“Placing Price”) raising approximately £1.9 million (approximately £1.8 million after expenses) (“Placing Proceeds”). The Placing Price represents a discount of 2.7% to the closing mid-market price of 128.5p on 28 November 2006. [More] November 2006OHM, BP, and the University of Southampton to investigate CSEM for appraisal
Offshore Hydrocarbon Mapping plc (OHM), BP and the University of Southampton are to November 2006OHM Secures Vessel for Three-Continent Survery Programme. Offshore Hydrocarbon Mapping plc (“OHM”) has announced today that it has chartered a survey
The 81-meter CS Teneo has been chartered from marine services company Tyco November 2006OHM 2006 Annual Report [More] October 2006Jeffrey Garner joins OHM Board as Non-Executive Director Further to the board changes outlined in the announcement dated 17th October 2006, the Company is pleased to announce that Jeffrey Scott Garner has been appointed as a non–executive Director of the Company and Landon Clay has resigned from the Board. Jeffrey Scott Garner, aged 50, a US citizen, has been an investment manager since 1988. In 2000, he joined Boston (US) based, East Hill Management in the role of President and Managing Member of the General Partner of East Hill University Spinout Funds LP. Prior to that he was Chief Investment Officer, Investment Management at Cypress Tree Investment Management (1996 to 2000) and VP and Portfolio Manager, Investment Management, Eaton Vance Management (1988 to 1996). [More] October 2006Offshore Hydrocarbon Mapping Plc (‘OHM‘ or ‘the Company’) Preliminary Results for the Year ended 31 August 2006
• Turnover doubled to £10.4 million October 2006Offshore Hydrocarbon Mapping plc High Court Proceedings Offshore Hydrocarbon Mapping plc (the Company) notes the announcement made on the 4th October 2006 by Electromagnetic Geoservices AS (emgs) that it has launched proceedings in the High Court in London against the Company alleging infringement of one of emgs’ patents related to Seabed Logging. [More] September 2006Offshore Hydrocarbon Mapping and TGS to conduct further multi-client CSEM acquisition in Norway Following the success of the 2005 campaign, Offshore Hydrocarbon Mapping and TGS are to undertake a further series of multi-client Controlled Source Electromagnetic (CSEM) surveys in the Norwegian Sea and Troms III area, offshore Norway. Depending on favourable weather conditions, up to ten separate surveys will be acquired before the end of 2006. September 2006Trading update Offshore Hydrocarbon Mapping plc (“OHM” or the “Company”) (AIM:OHM) is pleased to report that it expects to end the fiscal year on 31 August 2006 with revenues significantly more than double those of the previous fiscal year, and with a pre-tax loss of less than half of the previous year, in the absence of unforeseen circumstances. The Company’s cash balance remains healthy.[More] July 2006Offshore Hydrocarbon Mapping plc is to conduct an extensive Controlled Source Electromagnetic June 2006OHM delivers preliminary report to Rockhopper Exploration. Offshore Hydrocarbon Mapping plc (“OHM” or The Company”) (AIM:OHM) has delivered a preliminary report to its client Rockhopper Exploration (“Rockhopper”) on the Controlled Source Electromagnetic (CSEM) surveys conducted earlier this year, over two areas within Rockhopper’s North Falkland Basin exploration acreage. Rockhopper has announced today that the preliminary CSEM results, when combined with the existing seismic data, give a positive indication consistent with the presence of hydrocarbons. Rockhopper has also cautioned, and OHM concurs, that further work is required on merging the recently acquired 2D seismic data, when it is processed and interpreted, with the CSEM data. A final report taking into account the new seismic data will be delivered to Rockhopper after the new seismic data is fully processed. [More] June 2006OHM and Rock Solid Images to cooperate on integration of electromagnetic data with well-bore and seismic data. Offshore Hydrocarbon Mapping plc (OHM) and Rock Solid Images (RSI) are working together to advance the integration of seismic and well log data with CSEM. May 2006OHM comment on University of Southampton Patent Case Appeal. Further to the announcements made on 22 July, 29 July and 15 September 2005, Offshore Hydrocarbon Mapping plc (“OHM” or the “Company”) today announces that the University of Southampton has agreed with Statoil to discontinue its appeal against the UK Patent Office ruling awarding a patent from the University to Statoil of Norway. The agreement was reached before the hearing was due to start and is awaiting sealing by the court. April 2006Interim results for the six months ended 28 February 2006. Offshore Hydrocarbon Mapping plc (OHM), the AIM listed provider of remote electromagnetic sensing services designed to detect the presence of offshore oil and gas, today announces its interim results for the six months ended 28 February 2006. February 2006Trading Update. Following the conclusion of a successful first half, Offshore Hydrocarbon Mapping plc (“OHM” or “the Company”) is pleased to announce trading which has exceeded the board’s expectations for the six months to 28 February 2006. In the absence of unforeseen circumstances the Directors anticipate that turnover and operating profit for the six months to 28 February will be in excess of that achieved for the full year to 31 August 2005. Cash resources are slightly ahead of the figure of £ 4.4 million reported at 31 August 2005. The Company expects to report its interim figures on the 25th of April 2006. [More] February 2006Offshore Hydrocarbon Mapping plc restructures Board. Robert (Bob) Auckland has now taken up his position as Finance Director. Concurrent with his appointment, the Company is progressing with the evolution of its Board, reflecting its development from a University spin out to a significant public company. Dr. Tony Raven, Professor Martin Sinha and David Norwood, who were instrumental in the formation and initial development of the company and key members of the pre IPO board are taking this opportunity to retire. Professor Sinha will continue to contribute his expertise to the company’s technical advances through the continuation of his consulting contract. [More] Oxford Biosensors LimitedDecember 2004Oxford Biosensors announces development agreement with Pfizer. Oxford Biosensors today announced an exclusive development agreement with Pfizer Inc to accelerate development of point-of-care diagnostic tests. Under the terms of the agreement, Pfizer will provide Oxford Biosensors with additional funding to accelerate development of Oxford Biosensor’s novel testing technology that enables multiple analyte detection from a single drop of blood. [More] Oxitec LimitedMarch 2007Oxitec has developed a strain of mosquito with the key features required to control the dengue fever mosquito. [More] March 2007Oxitec was selected for the Fast Company Magazine's 6th annual "Fast 50". Oxitec's method for controlling disease-spreading mosquitoes was chosen as one of the top 50 most promising profit-driven solutions for what ails the planet. [More] February 2007Oxitec announces new technology that will allow production of male-only populations of insect pests. [More] January 2007Oxitec is pleased to announce the appointment of two new senior scientists. Dr Martha Koukidou has joined the fruit fly control team, and Dr Krisztian Magori has joined the mosquito control team as a senior mathematical / economic modeller. [More] October 2006Dr Andrew McKemey joins Oxitec's Business Development team. Oxitec is pleased to welcome Dr Andrew McKemey to its Business Development team. Andrew has a BSc. from Bath in Applied Biology, an MSc. in crop protection from the University of Bristol and a PhD in Invertebrate Ecology from the University of Cardiff. He is joining us from Insect Investigations Ltd. in Cardiff, where he was Head of Field Studies. There he was responsible for running contract research insect control trials including efficacy and regulatory studies. [More] June 2006Oxitec runner-up in the Oxford and South East award for Innovation in Enabling Biotechnology , 2006. The award recognises innovation and enterprise in emerging technology-based life science businesses. Nominations were received for companies from Oxford and the South-East of England, and was open to companies based in Oxfordshire, Berkshire, Wiltshire, Hampshire, Surrey, Sussex or Kent. June 2006Oxitec announces technical breakthrough. "Transposon-free insertions for insect genetic engineering" has been published on-line in the journal Nature Biotechnology. The paper describes a method developed at Oxitec Ltd. in collaboration with Oxford University, which we believe will become the gold standard for genetic engineering of insects for safe field use. For more details, see http://www.nature.com/nbt/journal/v24/n7/abs/nbt1221.html March 200628 March, 2006. Ann Kramer joins Oxitec as Head of Business Development. We are pleased to announce that Ann Kramer has joined Oxitec as Head of Business Development. Ann joins us from Syngenta, in Basle, where she was Manager, Mergers and Acquisitions.[More] Oxxon TherapeuticsMarch 2007Oxxon Therapeutics to be Aquired by Oxford BioMedica Acquisition consolidates immunotherapy assets Oxford, UK – 12 March 2007: Oxxon Therapeutics Limited (‘Oxxon’), a leading therapeutic vaccine company, announced today that it has entered into an agreement to be acquired by Oxford BioMedica (LSE: OXB, ‘Oxford BioMedica’), the publicly traded biopharmaceutical company, based in Oxford, UK. Oxford BioMedica is focused on the development of novel gene-based therapeutics particularly in oncology, including therapeutic vaccines, and neurotherapy. The transaction values Oxxon at £16 million, to be satisfied by the issue of Oxford BioMedica shares.
October 2006Oxxon Therapeutics Successfully Defends Challenge to Core Patent.
Oxxon Therapeutics announces today that the Opposition Division of the European Patent Office (EPO) has maintained key claims of Oxxon’s European Patent EP0979284, despite challenges initiated by seven biopharmaceutical companies. June 2006Oxxon Therapeutics' HI-8™ Mel Therapeutic Vaccine demonstrates potential for treatment of advanced metastic melanoma. Oxxon Therapeutics today presents data from its Phase II clinical study of its novel Hi-8™ MEL therapeutic vaccine in patients with advanced non-resectable melanoma, at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Atlanta, GA. The Phase II dose-escalation study has met its clinical endpoints, demonstrating that immunisation with Oxxon’s Hi-8™ MEL therapeutic vaccine is well tolerated at all doses and shows clinical benefit in HLA-A2 positive patients. [More] April 2006Oxxon Therapeutics to Present Phase IIA Clinical Efficacy Data for its HI-8 ™ HBV Therapeutic Vaccine as a Treatment for Chronic Hepatitis B. Oxxon Therapeutics is pleased to announce that efficacy data from its recently completed Phase IIa clinical study of its novel Hi-8™ HBV therapeutic vaccine in patients with chronic hepatitis B will be presented at the 41st Annual Meeting of the European Association for the Study of the Liver (EASL), which will be held in Vienna, Austria between 26-30 April 2006. The efficacy data will be presented in a ‘late-breaker’ poster from 19.00hrs (CET) on Thursday 27 April during the inaugural poster session by Dr
Joerg Schneider and April 2006Oxxon Therapeutics Appoints Craig R. Smith, M.D. Chairman and John Berriman Executive Deputy Chairman of its Board of Directors. Oxxon Therapeutics today announced the appointment of Dr Smith has been a member of Oxxon’s Board of Directors since June 2005 and is currently a board member of several Plasso LimitedJuly 2006Surface Critical Technology. Carclo Technical Plastics, a Division of Carclo plc, and Plasso Technology Ltd. have entered into a collaboration to jointly develop the market for advanced plastic medical devices combined with active surface coatings. The two companies will service the growing demand for sophisticated components within the diagnostic, sensor, pharmaceutical and medical device sectors. Commenting, Martin Day - Sales & Marketing Director of Carclo Technical Plastics - stated that the rapid development of, for example, point-of-care diagnostic devices that allow GPs to obtain diagnoses at the bed-side, require a new approach to design and materials. "We’re seeing a demand for sophisticated, often miniaturised components that can manage the flow of fluids and molecules from one part of the device to another and then immobilise the sample compound to allow the diagnostic test to take place. This is where Plasso’s surface technology plays a key role in the optimisation of the flow of liquids in these devices and the binding of molecules to surfaces to improve detection."[More] June 2006Plasso Technology Ltd has been awarded a Small Business Research Initiative (SBRI) grant by The Biotechnology & Biological Sciences Research Council (BBSRC) to develop a novel research tool that will enable researchers to select optimum surface chemistries for their biological procedures. Surface chemical gradients will be fabricated by a novel means using plasma deposition. Use of plasma allows the deposition of gradients that are reproducible and stable and suitable for use with common biological procedures and reagents. Plasma fabricated surface chemical gradients are ideal for developing as “research tools”, and as means to identify optimal surface chemistries on which to carry out biological procedures. In this study, surface chemical gradients will be fabricated onto which gradients of varying densities of the "delta-1" and "jagged-1" ligands will be superimposed. [More] January 2006The Biochemical Society meeting on Cytokine/proteoglycan interactions: biology and structure at the Royal Holloway, University of London (9th & 10th January) will focus on current advances in the study of different cytokine families, exploring the structural biology and physiological significance of their interactions with proteoglycans. It is increasingly emerging that a large number of structurally diverse cytokines bind to glycosaminoglycans a type of polysaccharide that is ubiquitous on the surface of cells. [More] Prolysis LimitedJanuary 2007Prolysis receives a £3.48 million Seeding Drug Discovery award from the Wellcome Trust New antibacterials being developed to tackle MRSA superbug A novel antibacterial medicine that kills the superbug MRSA is being developed under a new scheme launched by the Wellcome Trust. The Seeding Drug Discovery initiative is aimed at catalysing the development of new drugs in areas of unmet need. Prolysis, an R&D company based in Oxford, has received one of three inaugural Seeding Drug Discovery awards for its new antibacterial compounds aimed at tackling life-threatening, drug-resistant infections caused by staphylococci, including MRSA. The bacterium Staphylococcus aureus can infect wounds, including those resulting from medical procedures conducted in hospitals. It may then spread further into the body and cause serious infections such as blood poisoning. Methicillin-resistant Staphylococcus aureus, or MRSA, is a form of the bacterium that is resistant to the drug methicillin and a number of other antibiotics and tends to be more difficult to treat. [More] April 2006Prolysis invited to present at Superbugs & Superdrugs conference in London. Prolysis has been invited to present at Superbugs & Superdrugs conference in London. Director of Research, Dr Lloyd Czaplewski will present a talk entitled: Creating and progressing a portfolio of novel antibacterials. This presentation will describe Prolysis' antibacterial drug discovery engine and provide an update on the progress of novel inhibitors acting on bacterial cell division and DNA supercoiling. April 2006Professor Jeff Errington FRS completes the relocation of his research team. Professor Jeff Errington FRS takes up his position as the Director of the Institute for Cell and Molecular Biosciences at the University of Newcastle upon Tyne. Jeff is Prolysis' founder and Chief Scientific Officer. He has relocated and expanded his research team with the completion of his move from the University of Oxford to the Institute at Newcastle. February 2006Prolysis presents at a Gordon Research Conference in Ventura, CA. Prolysis is to present a programme poster at the New Antibacterial Discovery & Development Gordon Research Conference to be held in Ventura, CA on the 5 - 9th March 2006. The poster is entitled: Antibacterial activity of novel small-molecule inhibitors of bacterial type II topoisomerases in vitro and in a murine model of staphylococcal infection. ReOx LimitedAugust 2003Oxford Spin-out to Develop New Drug Therapies Based on the Hypoxic Response Isis' latest spin-out company. ReOx Ltd, is set to develop potential therapies for a huge range of diseases, from heart disease to stroke, using world-leading expertise in biology and chemistry. The company was spun out this summer and has raised £2 million in capital investment. [More] Stratophase LimitedOctober 2005Fire at Southampton University. On Sunday morning 29th October a fire caused significant damage to the clean room facilities of both the Microelectronics and Optoelectronics Research Center at the University of Southampton. Stratophase was originally spun out of the ORC at the University of Southampton over two years ago. Whilst we continue maintain a strong relationship with the ORC, over the past two years we have progressively commercialised and transferred our processing technology into our own facilities and we are happy to re-assure everybody that there has been no impact to Stratophase’s operation. [More]
New ThorLabs product line. Look for Stratophase's line of products in the new ThorLabs catalogue. We have taken our highest demand products and elected to sell them through and exclusive deal with ThorLabs, so purchasing our products is easier than ever. [More] Surface Therapeutics Limited[More] ThromboGenics LimitedMarch 2007GO Capital Becomes Major Shareholder in ThromboGenics GO Capital Acquires Shares from Biggar Limited, the Company’s Largest Shareholder
Leuven, Belgium – 27 March, 2007 – ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular disease, today announced that Global Opportunities Capital Asset Management BV, also known as GO Capital, a Dutch-based asset manager, has acquired 1.2 million shares in the company, representing approximately 5.4% of its outstanding shares. The acquisition of this stake from Biggar Limited makes GO Capital one of ThromboGenics’ major shareholders. As a result of this transaction, Biggar’s holding in March 2007Harvard Club of Belgium Harvard Club of Belgium’s Leadership Prize < About the Prize and this year’s winner: The Harvard Club of Belgium Prize is awarded annually to an individual or organization whose accomplishments reflect the University’s legacy of integrity and leadership and that have lasting impact on Belgium’s economic, cultural, scientific or socio-political landscape. The Club’s Board of Directors has selected Dr. Désiré Collen to be this year’s recipient of the Harvard Leadership Prize. Dr. Collen is an outstanding leader in sciences, with a distinguished academic record and an extraordinary ability to translate scientific insights into impressive business opportunities. [More] February 2007ThromboGenics – Business Update and Half Year Results to end November 2006 Leuven, Belgium - February 15, 2007 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular disease, today announces a business update and its financial results for the six month period ending November 2006. During the last nine months, ThromboGenics has made significant progress, becoming a listed company, strengthening its management team and advancing its product pipeline. [More] February 2007ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials for Anticoagulant TB-402 Leuven, Belgium and Lund, Sweden – 12 February 2007 – ThromboGenics NV (Euronext Brussels: THR) and BioInvent International AB (OMXS:BINV) announced today that they have received approval from the Danish Medicines Agency to initiate a Phase I clinical trial of the novel anticoagulant, TB-402. TB-402 is a human antibody binding to Factor VIII, which plays a crucial role in the coagulation of the blood. The project is being developed within the framework of the alliance between ThromboGenics and BioInvent. [More] January 2007ThromboGenics and Geymonat Announce Euro 2 Million EU Grant for VASOPLUS Pro-Angiogenesis Programme VASOPLUS Research Consortium Includes Roche Diagnostics and Distinguished Academic Centres Leuven, Belgium - January 15, 2007 -ThromboGenics NV (Euronext Brussels: THR) and Geymonat SpA announced today that the European Union has approved a Euro 2 million grant to the VASOPLUS consortium, a development programme for a new class of pro-angiogenesis agents. The funded research for VASOPLUS will be conducted within a consortium that will comprise ThromboGenics, Geymonat, Roche Diagnostics (Germany), Eurogentec S.A. (Belgium) and three expert academic groups - University of Leuven (Cardiology Department) in Belgium, Consiglio Nazionale delle Ricerche in Italy, and University of the Free State in South Africa. [More] January 2007ThromboGenics Initiates Phase IIb U.S. Clinical Trial of Microplasmin in Vitrectomy December 2006ThromboGenics and BioInvent Awarded Euro 2 Million EU Grant for ANGIOSTOP Anti-Angiogenesis Programme
Leuven, Belgium and Lund, Sweden - December 28, 2006 - ThromboGenics NV (Euronext Brussels: THR) and BioInvent International AB (OMXS:BINV) announced today that they have received a Euro 2 million grant from the European Union for the joint development of a new class of anti-angiogenesis agents. The new agents will be based on antibodies against Placental Growth Factor (PlGF). This EU grant will support the research efforts initiated by ThromboGenics and BioInvent in 2004 as part of a strategic collaboration. The funded research will be conducted within the ANGIOSTOP consortium that will also comprise four expert academic groups from Belgium, December 2006ThromboGenics Announces License Agreement with Bharat Biotech for Novel Thrombolytic Agent. Deal Paves Way for Commercialization in Developing Countries.
ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular disease, today announced that it has completed a license agreement with Bharat Biotech International Limited (Hyderabad, India) for manufacturing, clinical development and commercialization of THR-100*, a novel variant of November 2006ThromboGenics Receives IND Clearance from FDA for Microplasmin in Vitrectomy Company to start Phase IIb in the U.S. by the end of the year. ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular disease, today announced that the U.S. Food and Drug Administration (FDA) completed its review of the Company’s Investigational New Drug (IND) application for microplasmin intraocular injection. The FDA considers the proposed MIVI III (Microplasmin for Vitreous Injection III) trial safe to initiate, and ThromboGenics will proceed with patient recruitment for this study. Preliminary positive results of a Phase IIa clinical trial in Europe demonstrated that Microplasmin could induce PVD (posterior vitreous detachment) to ease vitrectomy surgical procedure. [More] October 2006Promising Microplasmin Phase IIa Results Presented at International Ophthalmology Meeting Results Provide Platform for Further Clinical Trials in “Back of the Eye” Diseases. ThromboGenics NV (Euronext Brussels: THR), a
biotechnology company focused on vascular disease, announces the first presentation of the
results of the MIVI-I Phase IIa trial (Microplasmin In VItrectomy). The presentation covering all 60 patients treated in the study will be made today by Prof. dr. Marc de Smet, the Principal October 2006Roche Diagnostics announces agreement with ThromboGenics and Geymonat on diagnostic applications of PlGF (Placental Growth Factor) September 2006ThromboGenics NV Announces Update on its Microplasmin Development Strategy for Peripheral Vascular Disease. September 2006ThromboGenics NV Announces Initiation of Phase IIa Trial Evaluating Microplasmin for the Intra-arterial Treatment of Acute Stroke (MITI-IA Trial). ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular disease, announces today the initiation of a Phase IIa clinical trial to evaluate microplasmin for the intra-arterial treatment of stroke. The study, which is called the Microplasmin MITI-IA Trial (Microplasmin In Treatment of Ischemic Stroke – Intra-Arterial), is the second study that ThromboGenics has initiated to assess the benefits of microplasmin for the treatment of acute ischemic stroke. The first study, called MITI-IV, is evaluating the intra-venous administration of microplasmin for the treatment of acute stroke. Preliminary results from the MITI-IV trial, which is ongoing, are expected to be available in the second half of 2007. [More] September 2006ThromboGenics Announces Completion of Enrolment for Its Phase IIa Trial to Assess Microplasmin’s Utility in “Back of the Eye” Diseases. ThromboGenics NV (Euronext Brussels: THR) today announced that it has completed the enrolment and treatment of all 60 patients to be included in its MIVI-I trial (Microplasmin In VItrectomy). The MIVI-I trial is a Phase IIa, open-label, dose-ranging trial evaluating the effects of intraocular injection of recombinant microplasmin in patients undergoing vitrectomy (surgery to treat vitreoretinal disorders), which was carried out in a multi-centre European study. The objective of this trial is to evaluate the effect of microplasmin as a surgical adjunct to vitrectomy for induction of PVD (posterior vitreous detachment), and to optimize the correct dosing regime for further clinical studies. [More] August 2006Financial Calendar 2006/2007 ThromboGenics (Euronext Brussels: THR), a biopharmaceutical company focused on the development of novel medicines for the treatment of vascular disease, today announces its Financial Calendar for 2006/2007, its first financial year as a public company. Due to the timing of its initial public offering, ThromboGenics 2006/2007 financial year will cover the 19 month period to end December 2007.[More] August 2006ThromboGenics Appoints Chris Buyse as New Chief Financial Officer and Director. Leuven, Belgium – 16th August, 2006 – ThromboGenics (Euronext Brussels: THR), a biopharmaceutical company focused on the development of novel medicines for the treatment of vascular disease, announced today that it has appointed Chris Buyse as its new Chief Financial Officer (CFO). Mr Buyse, who until recently was CFO of CropDesign NV, will take up his duties immediately. Mr Buyse replaces Andrew Guise in the management team and will be taking up his position on the Board. Having helped complete the IPO, Dr Guise will go on to pursue other business interests. [More] July 2006Full exercise of the Over-Allotment Option of ThromboGenics public offer. ThromboGenics (Euronext Brussels: THR), a biopharmaceutical company focused on the development of novel medicines for the treatment of vascular disease, announced today that the Over-Allotment Option granted by the selling shareholders to the Lead Manager, KBC Securities, was fully exercised at the offer price, i.e. €4.50, in accordance with the terms and conditions described in the prospectus. Following the exercise of this option, the total number of shares sold by the selling shareholders amounts to 777,778. All these shares are already allocated and tradable on the regulated market of Eurolist by Euronext Brussels. [More] July 2006ThromboGenics raises the envisaged €35 million in its IPO and additionally €3.5 million in over-allotment shares will be allocated. ThromboGenics, a biopharmaceutical company focused on the development of novel medicines for the treatment of vascular disease, announced today that it has successfully completed its initial public offering (IPO) on the Eurolist by Euronext Brussels. Pursuant to the offering, 7,777,778 new shares, equivalent to €35 million, will be issued by ThromboGenics, and additionally, 777,778 over-allotment shares, equivalent to €3.5 million will be allocated. The IPO price amounts to €4.50 per share. Shares will start trading as of 7th July on the Eurolist by Euronext Brussels under the symbol THR. [More] June 2006On June 2, 2006 ThromboGenics, a biopharmaceutical company focused
February 2005The Interbrew-Baillet Latour Health Prize, worth one hundred and fifty thousand euro, is awarded every year to a key figure for activities pursued within the framework of a medical science research project and/or practical applications of that research. It is the biggest scientific prize awarded in Belgium. The Interbrew-Baillet Latour 2005 Health Prize for “Genetics and Cardiovascular Diseases” has been awarded to Professors Désiré COLLEN and Peter CARMELIET of the "Katholieke Universiteit Leuven" (Belgium). [More] Zyentia LimitedDecember 2006December 2006 Zyentia Ltd announces Research Collaboration with Potentia Pharmaceuticals Cambridge, UK; 20 December, 2006. Zyentia Ltd, a leading company providing solutions to protein misfolding and aggregation, today announced that it has entered into a research collaboration with Potentia Pharmaceuticals (Louisville, KY). Under the terms of the collaboration Potentia will have access to Zyentia proprietary AggreSolve™ platform to characterize some of its compounds. [More] July 2005Zyentia’s proprietary algorithms to modify protein aggregation. PNAS http://www.pnas.org/papbyrecent.shtml is going to publish a research study carried out by Zyentia’s scientists in collaboration with the University of Cambridge (UK). The work includes an exemplification of how Zyentia’s proprietary technologies can be applied to re-engineer polypeptide molecules to prevent their aggregation. Zyentia has expressed its intention to enter in negotiations with pharmaceutical or biotechnological partners interested in this technology, aimed to explore potential collaborations or licensing opportunities. [More] November 2004Zyentia announces research collaboration in Parkinson’s disease. Zyentia Limited announced today that it had entered into a research
collaboration agreement with the Institute of Biomedical Research of Barcelona -
Parc Científic de Barcelona (IRBB-PCB) to identify novel treatments for Parkinson’s disease. The principal collaborator in Barcelona will be Professor Ernest Giralt. |